CytomX Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-20.7M | $-18.2M | $-26.5M | $-14.2M | $-154.0K | $23.5M | $18.9M | $5.7M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | $36.0K | $37.0K | $37.0K | $36.0K | $37.0K | $36.0K | $37.0K | $36.0K |
| Stock-Based Compensation | $2.6M | $4.7M | $1.5M | $1.4M | $1.4M | $2.0M | $1.9M | $2.0M |
| Net Cash from Operating Activities | $-18.1M | $-25.5M | $-23.2M | $-15.5M | $-15.8M | $-21.0M | $-19.9M | $-20.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $0 | $201.0K | $-127.0K | $27.0K | $119.0K | $80.0K | $19.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $6.0M | $-192.8M | $-14.4M | $439.0K | $-76.4M | $30.6M | $15.1M | $18.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $511.0K | $234.5M | $16.6M | $253.0K | $93.6M | $0 | $2.2M | $0 |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-18.1M | $-25.5M | $-23.4M | $-15.4M | $-15.8M | $-21.2M | $-20.0M | $-20.7M |